Picture courtesy ph.news.yahoo.com
Hong Kong: Two Chinese COVID-19 vaccine candidates, specifically developed to target the Omicron variant of coronavirus, have been approved for clinical trials as boosters in Hong Kong, Reuters reported.
The vaccines have been developed by units of China National Biotec Group (CNBG), according to Sinopharm subsidiary.
Both vaccine candidates contain inactivated or ‘killed’ Omicron virus and are similar to the two Sinopharm vaccines being used in China. They will be tested in adults who have already received two or three vaccine doses, CNBG said in a statement.
A study in China showed that a fourth dose of Sinopharm’s vaccine BBIBP-CorV did not significantly raise antibody levels against Omicron when administered six months after a third booster dose.
Scientists around the world are studying upgraded injections against Omicron, as vaccines based on earlier strains have not been very effective in neutralizing the highly transmissible variant.
New Delhi: Iran fired air defence batteries early Friday morning after three explosions were heard…
New York: As many as 28 Google employees have lost their jobs for showing dissent.…
Malkangiri: In a major breakthrough, BSF personnel and local police unearthed two arms dumps of…
Mumbai: A recent report claimed that Team India captain Rohit Sharma, Rahul Dravid and chief…
Nabarangpur: Congress candidate for election to Odisha's Nabarangpur Lok Sabha constituency Bhujabal Majhi filed his…
Mumbai: Neena Gupta and West Indies cricket legend Vivian Richards are set to be grandparents.…
New Delhi: The Aam Aadmi Party (AAP) alleged on Thursday that a conspiracy was being…
Bhubaneswar: The Commissionerate Police has arrested four cyber fraudsters, including a couple, for allegedly duping…